EMA recommends approval of ovarian cancer drug

Organisation: Position: Deadline Date: Location:

A European Medicines Agency (EMA) panel has recommended the approval of Tesaro Inc’s key drug, niraparib, for the treatment of recurrent ovarian cancer, reports Reuters Health. The recommendation comes months after the drug’s approval and launch in the US.

Epithelial ovarian, fallopian tube or primary peritoneal cancer affects the tissue covering the ovary or lining of the fallopian tube or abdominal wall.

The report says niraparib kills cancer cells by inhibiting the production of proteins called poly-ADP ribose polymerase (PARP), which helps repair damaged DNA strands, thereby hastening the death of some types of cancer cells.

Effective PARP inhibitors are sought after by drug-makers because of their potential to be used in combination with other types of cancer treatments to create new breakthrough treatments.

Reuters Health report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.